NICEATM is interested in receiving available data and information on approaches and technologies currently used to identify substances with the potential to cause acute systemic toxicity. This information will be used to assess the state of the science and determine technical needs for non-animal test methods to evaluate the potential of chemicals to induce acute systemic toxicity.
Acute inhalation toxicity tests evaluate the potential for chemicals to cause illness or injury when inhaled for a short period of time. NICEATM and collaborators have organized webinars and workshops to review the state of the science of alternatives to animal use for acute inhalation toxicity testing and identify opportunities for replacement of animal use.
Representatives from regulatory agencies, academia, and industries developed strategies for advancing alternative methods for product safety testing that meet the needs of regulatory agencies at a 2015 workshop on Alternative Approaches for Identifying Acute Systemic Toxicity: Moving from Research to Regulatory Testing. During this workshop, several resources were identified as necessary for meaningful progress in identifying and implementing alternatives: high quality reference data, training on use and interpretation of computational approaches, and global harmonization of testing requirements. The workshop proceedings have been submitted for publication and include conclusions and recommendations from the participants on in vitro and in silico approaches to reduce or replace animal use for acute toxicity testing.
NICEATM evaluated the use of high-throughput screening (HTS) data from the interagency Tox21 and the U.S. Environmental Protection Agency’s (EPA) ToxCastTM programs to reduce animal use for acute oral toxicity testing. The HTS data were analyzed for correlation and model fit to rat oral LD50 data to determine which tests or combinations of tests best characterized the rat oral toxicity data. The analyses suggested that, for some substances, combinations of data from in vitro and small organism assays, such as the zebrafish, offer promise for predicting rat oral toxicity outcomes. This project was described in a poster presentation (Polk et al.) at the 2015 Annual Meeting of the Society of Toxicology.
Acute oral and dermal systemic toxicity test data are used to determine hazard label requirements needed to protect pesticide users, workers, and handlers. Dermal systemic toxicity test data are also used to establish the type of personal protective equipment required for occupational pesticide users.
In an effort to determine if acute oral toxicity data can be used to reliably assign EPA acute dermal hazard classifications, NICEATM collected acute oral toxicity data for pesticide active ingredients and EPA provided similar information for pesticide formulations. NICEATM performed reviews of the data so that only high quality data were used to evaluate the usefulness and limitations of the acute oral toxicity data in estimating dermal hazard classifications. The outcome of this effort may result in reduced animal use for pesticide testing. EPA used a portion of this analysis to support draft guidance for waiving the acute dermal toxicity test for pesticide formulations. This project was summarized in a poster (Paris et al.) presented at the 2015 Annual Meeting of the Society of Toxicology.
To assist with ongoing efforts, NICEATM formed an interest group with members from federal agencies, nongovernmental organizations, international validation organizations, and national and international animal welfare organizations. The focus of this group is to identify alternative methods for acute oral toxicity testing and determine the steps necessary to advance their implementation.
The European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM) coordinated a validation study of two in vitro assays to evaluate human liver metabolism and toxicity. Representatives from NICEATM and ICCVAM participated on the management team for this validation study.
In humans and other animals, chemical metabolism often involves liver enzymes called cytochrome P450s (CYPs). Interactions between CYP enzymes and chemicals or drugs can alter CYP enzyme activity, causing hormonal disturbances, increased liver weight, drug–drug interactions, and other toxic effects. Alteration of CYP enzyme activity can potentially increase or decrease chemical toxicity, so measuring CYP enzyme activity is important to the development of in vitro toxicity assays.
An EURL ECVAM study to assess the potential for CYP enzyme induction at clinically relevant doses of pharmaceuticals in a human hepatoma cell line (HepaRG®) and cryopreserved human liver cells was completed in 2013. This study provides a starting point for the development of novel in vitro platforms to assess chemical and drug metabolism and toxicity, with the ultimate goal of providing a metabolically competent in vitro alternative for long-term toxicity studies.
The EURL ECVAM validation report for this study was submitted to the EURL ECVAM Scientific Advisory Committee for peer review in 2014. A draft test guideline for in vitro measurement of CYP enzyme induction is currently under consideration by the Organisation for Economic Co-operation and Development (OECD).
In vitro methods that use mammalian cell cultures and various cytotoxicity endpoints have been proposed as alternatives to in vivo acute oral systemic toxicity tests that use rodents. In vitro test methods that measure basal cytotoxicity (general cytotoxicity that affects structures or processes intrinsic to all cell types) are not currently regarded as suitable replacements for rodent acute oral toxicity tests. However, some methods may be useful for establishing the starting dose for acute oral toxicity tests.
ICCVAM recommends, where appropriate, the use of validated in vitro basal cytotoxicity tests in a weight-of-evidence approach to determine starting doses for acute oral systemic toxicity tests before using animals. Using these in vitro methods where appropriate is expected to reduce the number of animals required for each toxicity test.
The use of in vitro cytotoxicity test methods to reduce animal use in acute oral systemic toxicity testing was evaluated at a Workshop on In Vitro Methods for Assessing Acute Systemic Toxicity (2000). A Guidance Document on Using In Vitro Data to Estimate In Vivo Starting Doses for Acute Toxicity was prepared by ICCVAM with the assistance of the workshop participants.
NICEATM, ICCVAM, and international partners sponsored a workshop to explore alternative methods for acute chemical safety testing. The goals of this February 2008 meeting of international experts in the fields of in vitro and in vivo toxicology and human and veterinary medicine were to:
The oral up-and-down procedure (UDP) is an alternative to the traditional oral median lethal dose (LD50) test that reduces animal use. In the oral UDP, one animal is tested at a time, and the response of each animal to a test substance determines whether the next animal receives a higher or lower dose. A peer review panel sponsored by NICEATM and ICCVAM met in 2000 and 2001 to evaluate the revised oral UDP and develop recommendations. U.S. regulatory agencies adopted the ICCVAM recommendations on the revised oral UDP in 2003 and now accept oral UDP methods issued by OECD and the EPA, which have replaced the conventional acute oral systemic toxicity test method.